D. Boral Capital Reiterates Buy Rating on Carisma Therapeutics Inc (CARM)

D. Boral Capital analyst Jason Kolbert reiterated a Buy rating and $24.00 price target on Carisma Therapeutics Inc (NASDAQ: CARM).

The analyst comments "We model 0525 in HER2 Breast Cancer (BC). We apply a probability of success factor of just 30% and use a 30% discount rate (r). We assume additional capital will be raised in our final share count. We then apply these projections to our Free Cash Flow to the firm - FCFF, discounted EPS - dEPS, and sum-of-the-parts - SOP models, which are equal-weighted, averaged, and rounded to the nearest whole number to derive our 12-month price target of $12.00. To this we add a technology platform value as success in BC means that CAR-M works and this has broad implications for the company that at minimum equal the opportunity in BC. We add $12.00 of platform value to derive a $24.00 target valuation.

For an analyst ratings summary and ratings history on Carisma Therapeutics Inc click here. For more ratings news on Carisma Therapeutics Inc click here.

Shares of Carisma Therapeutics Inc closed at $1.01 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy